The PBM Price Transparency and Accountability Act requires pharmacy benefit managers (PBMs) to be more transparent about drug pricing and ensure accurate payments to pharmacies. It establishes national average drug acquisition cost benchmarks for Medicaid, prohibits PBMs from keeping excessive profits through "spread pricing," and mandates detailed reporting of drug pricing, rebates, and fees. The bill affects Medicaid programs, Medicare Part D plans, and the PBMs that negotiate drug prices on behalf of insurers. It includes enforcement mechanisms like civil penalties for non-compliance and requires PBMs to report detailed pricing information to the Secretary of Health and Human Services.
The Medicare-X Choice Act of 2025 would establish a new public health insurance option called the "Medicare Exchange health plan" available through health insurance exchanges starting in 2028 for eligible individuals who are not enrolled in traditional Medicare. The plan would offer silver and gold coverage levels with no cost-sharing for primary care services, and would reimburse healthcare providers at Medicare rates. Healthcare providers enrolled in Medicare or Medicaid would be required to participate in this public plan, and the bill includes provisions to collect data addressing health disparities and improve care coordination. The plan would be funded through $1 billion in appropriations for each of two funds to establish and administer the program, while maintaining existing Medicare benefits and trust funds.
S 3353, the Relief for Farmers Hit with PFAS Act, establishes a federal grant program to assist commercial farms and agricultural land affected by PFAS (chemicals found in some industrial products) contamination. Eligible states, tribes, or territories can receive funds to cover costs like monitoring health impacts, compensating for contaminated land or crops, upgrading equipment, conducting research on remediation, and providing financial aid to affected farmers. The program authorizes $500 million over five years (2026-2030), with funds prioritized for direct assistance to producers facing financial losses due to PFAS contamination. It requires annual reporting on fund usage and establishes a task force to advise on PFAS-related agricultural programs.
This bill creates two pathways to help high school students earn college credit while in high school and graduate early. The "early college fast track pathway" allows students to take college-level courses (like AP, IB, or dual enrollment) that count toward a degree, while the "early high school graduation pathway" lets students graduate in 3 years without needing remedial college courses and provides a scholarship for college. States would receive federal grants to implement these pathways, requiring them to align high school curriculum with college requirements, create statewide credit transfer agreements, and ensure credit transfer between institutions. The bill also changes Pell Grant rules to allow eligible high school students in these pathways to receive Pell Grants without counting toward the usual 12-semester limit. It requires states to track participation and outcomes, particularly for historically underrepresented students.
The SAFE Chips Act of 2025 requires U.S. exporters to obtain government licenses before sending advanced computer chips to "foreign adversary countries" (including China, Hong Kong, and Macau) or to entities owned by such countries. It defines "advanced integrated circuits" using specific technical standards, such as high processing power (e.g., 4,800+ performance points) or bandwidth (e.g., 4,100+ gigabytes per second), excluding chips designed for data centers. The bill mandates license denials for these exports and allows the Commerce Secretary to update technical definitions after 30 months, with required Congressional briefings on national security impacts. This directly affects chip manufacturers and companies exporting to specified regions, imposing strict controls on advanced semiconductor trade.
This bill designates the Museum of the Blind People’s Movement (currently located at the National Federation of the Blind Jernigan Institute in Baltimore, Maryland) as the National Museum of the Blind People’s Movement. It formally recognizes the museum, operated by blind individuals, as the first national institution dedicated to preserving and showcasing the history of blind people’s contributions and struggles in the U.S. The museum already collects artifacts, documents, and literature documenting the blind community’s collective achievements and civil rights efforts since the 1940s. The bill’s key provision is this official congressional designation, elevating the existing museum as a national platform for education and awareness about blind people’s movement.
HR 6449, the "DO NOT Call Act," amends the Telephone Consumer Protection Act of 1993 to strengthen penalties for illegal robocalls. It increases criminal penalties for willful violations to up to one year in prison (or three years for aggravated offenses like repeated high-volume calls or calls intended to support felonies), and raises fines for inaccurate caller identification from $10,000 to $20,000 per violation. The bill directly affects businesses and entities making unsolicited calls without consent, including those using auto-dialers or prerecorded messages. Key provisions define "calls" broadly to include unsolicited texts sent via auto-dialers without prior permission.
HR 6423, the HELP Copays Act, requires health insurance plans and coverage to count financial assistance from non-profits or drug manufacturers toward patient cost-sharing limits like deductibles and copayments. This directly affects patients enrolled in health insurance who receive such assistance for prescription drugs, ensuring the help they get reduces their out-of-pocket costs faster. The bill amends key health laws to mandate that these payments are included when calculating whether a patient has met their deductible or copayment threshold. The change applies to all prescription drugs, including specialty drugs and those subject to prior authorization, but does not alter how insurers manage drug access through tools like step therapy. It takes effect for plan years starting in 2026.
This Senate resolution (SRES 525) condemns the Iranian government's ongoing, state-sponsored persecution of the Baha'i minority, citing decades of systemic abuses including executions, job dismissals, education bans, and property confiscations. It references UN reports and Human Rights Watch findings documenting Iran's violation of international human rights treaties, such as the Universal Declaration of Human Rights and the International Covenant on Civil and Political Rights. The resolution calls on Iran to immediately release imprisoned Baha'is, end discriminatory policies restricting their education and employment, and cease hate propaganda, while urging the U.S. President and Secretary of State to impose sanctions on Iranian officials responsible for these abuses.
HRES 925 is a non-binding resolution condemning the Iranian government's ongoing persecution of the Baha'i religious minority. It directly affects Baha'is in Iran, who face systemic discrimination, imprisonment, denial of education and employment, and violence due to their faith. The resolution calls on Iran to immediately release Baha'i prisoners, end hate propaganda targeting them, and reverse policies banning their access to education and jobs. It also urges the U.S. President and Secretary of State to demand Iran's compliance and use existing sanctions authorities against officials responsible for human rights abuses against Baha'is.
This bill establishes two federal prize competitions to advance research on two key AI safety areas: interpretability (making AI decisions understandable to humans) and adversarial robustness (resisting malicious attacks that cause harmful outputs). The Secretary of Homeland Security must launch these competitions within 270 days of enactment, consulting with agencies like the National Institute of Standards and Technology and AI industry experts. Competitions will evaluate submissions based on practical value in high-risk AI applications, such as healthcare or finance, and require participants to submit frameworks or models. The Secretary must report to Congress 180 days after the competitions end, assessing research gaps and suggesting policy actions. The bill authorizes $10 million in funding for these competitions over fiscal years 2026-2030.
The LAB Personnel Act of 2025 (S 3334) protects the laboratory workforce at the Drug Enforcement Administration (DEA) from hiring freezes or workforce reductions caused by budget cuts or fund reprogramming. It directly affects DEA forensic lab staff, including forensic chemists, fingerprint specialists, digital forensic examiners, and other defined roles in DEA forensic laboratories. The bill mandates that these positions be exempt from reductions related to spending constraints, while clarifying that it does not prevent the Attorney General from managing staff under existing misconduct or performance procedures. This is a concrete policy change to maintain staffing levels in DEA forensic operations.
